• K. P. Mayolo-Deloisa Departamento de Biotecnología e Ingeniería de Alimentos, Centro de Biotecnología-FEMSA
  • M. Rito-Palomares Departamento de Biotecnología e Ingeniería de Alimentos, Centro de Biotecnología-FEMSA
Keywords: PEG, PEGylation, therapeutic proteins, bio-conjugates


PEGylation is the covalent attachment of protein and/or peptide to poly(ethylene glycol). The poly(ethylene glycol) is a polymer, non toxic, non immunogenic, and FDA (Food and Drug Administration, USA) approved. In the last years, PEGylation has been used to improve the physicochemical properties of some proteins and therapeutic drugs; this technology has impacted heavily on the bio-pharmaceutical industry. PEGylation prolongs the body-residence time and stability, decreases the proteolysis and renal excretion. Since the emergence of this technology, some proteins have been PEGylated for the treatment of diseases including hepatitis C, leukemia, rheumatoid arthritis, etc. This review presents a description of the PEGylation development in the last years and the chemical procedures used to obtain some bio-conjugated products. Strategies of purification used to obtain PEGylated proteins are reviewed; purification is one of the major problems to establish suitable processes due to the fact that the reaction can generate bioconjugates with different degree of PEGylation. Finally the applications of PEGylated proteins and the future challenges that are identified for generic application are presented.


Abuchowski, A., McCoy, J.R., Palczuk, N.C., Van Es, T. y Davis, F.F. (1977). Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. The Journal of Biological Chemistry 252, 3582-3586.

Arduini, R.M., Li, Z., Rapoza, A., Gronke, R., Hess, D.H., Wen, D., Miatkowski, K., Coots, C., Kaffashan, A., Viseux, N., Delaney, J., Domon, B., Young, C.N., Boynton, R., Chen, L.L., Chen, L., Betzenhauser, M., Miller, S., Gill, A., Pepinsky, R.B., Hochman, P.S. y Baker, D.P. (2004). Expression, purification, and characterization of rat interferon-β, and preparation of an Nterminally PEGylated form with improved pharmacokinetic parameters. Protein Expression and Purification 34, 229-242.

Calceti, P., Salmaso, S., Walker, G. y Bernkop-Schnürch, A. (2004). Development and in vi vo evaluation of an oral insulin-PEG delivery system. European Journal of Pharmaceutical Sciences 22, 315-323.

Cisneros-Ruiz, M. (2006). Chromatographic separation of conjugates polymer-protein. PhD Thesis. Tecnológico de Monterrey. Monterrey, N.L. México.

Cisneros-Ruiz, M., Mayolo-Deloisa, K., Przybycien, T.M. y Rito-Palomares, M. (2009). Separation of PEGylated from unmodified ribonuclease A using sepharose media. Separation and Purification Technology 65, 105- 109.

Daly, S., Przybycien, T.M. y Tilton, R.D. (2005). Adsorption of poly(ethylene glycol)- modified ribonuclease A to a poly(lactide-coglycolide) surface. Biotechnology and Bioengineering 90, 856-868.

Delgado, C., Malik, F., Selisko, B., Fisher, D. y Francis, G.E. (1994). Quantitative analysis of polyethylene glycol (PEG) in PEG-modified proteins/cytokines by aqueous two-phase systems. Journal of Biochemical and Biophysical Methods 29, 237-250.

Delgado, C., Malmsten, M. y Van Alstine, J.M. (1997). Analytical partitioning of poly(ethyl-ene glycol)-modified proteins. Journal of Chromatography B 692, 263-272.

Dou, H., Zhang, M., Zhang, Y. y Yin, C. (2007). Synthesis and purification of monoPEGylated insulin. Chemical Biology & Drug Design 69, 132-138.

Fee, C.J. y Van Alstine, J.M. (2004). Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins. Bioconjugate Chemistry 15, 1304- 1313.

Fee, C.J. y Van Alstine, J.M. (2006). PEGproteins: reaction engineering and separation issues. Chemical Engineering Science 61, 924-939.

Fishburn, C.S. (2008). The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. Journal of Pharmaceutical Science 97, 4167-4183.

Gaberc-Porekar, V., Zore, I., Podobnik, B. y Menart, V. (2008). Obstacles and pitfalls in the PEGylation of therapeutic proteins. Current Opinion in Drug Discovery & Development 11, 242-250.

García-Arellano, H., Valderrama, B., Saab-Rincón y Vazquez-Duhalt, R. (2002). High temperature biocatalysis by chemically modified cytochrome C. Bioconjugate Chemistry 13, 1336-1344.

Graham, M.L. (2003). Pegaspargase: a review of clinical studies. Advanced Drug Delivery Reviews 10, 1293-1302.

Hamidi, M., Azadi, A. y Rafiei, P. (2006). Pharmacokinetic consequences of pegylation. Drug Delivery 13, 399-409.

Harris, J.M. y Chess, R.B. (2003). Effect of PEGylation on pharmaceuticals. Nature Reviews Drug Discovery 2, 214-221.

Kim, T.H., Lee, H. y Park, T.G. (2002). Pegylated recombinant human epidermal growth factor (rhEGF) for sustained release from biodegradable PLGA microspheres. Biomaterials 23, 2311-2317.

Kinstler, O., Molineux, G., Treuheit, M., Ladd, D. y Gegg, C. (2002). Mono-N-terminal poly (ethylene glycol)-protein conjugates. Advanced Drug Delivery Reviews 54, 477- 485.

Lee, H. y Park, T.G. (2002). Preparation and characterization of mono-PEGylated epidermal growth factor: evaluation of in vitro biologic activity. Pharmaceutical Research 19, 845-851.

Li, D., Manjula, B.N. y Acharya, A.S. (2006). Extension arm facilitated PEGylation of hemoglobin: correlation of the properties with the extent of PEGylation. The Protein Journal 25, 263-274.

López-Cruz, J.I., Viniegra-González, G. y Hernández-Arana, A. (2006). Thermostability of native and pegylated Myceliophthora thermophila laccase in aqueous and mixed solvents. Bioconjugate Chemistry 17, 1093- 1098.

Molek, J.R. y Zydney, A.L. (2007). Separation of PEGylated alpha-lactalbumin from unreacted precursors and byproducts using ultrafiltration. Biotechnology Progress 23, 1417- 1424.

Morar, A.S., Schrimsher, J.L. y Chavez, M.D. (2006). PEGylation of proteins: A structural approach. BioPharm International, 34-48.

Pabst, T.M., Buckley, J.J., Ramasubramanyan, N. y Hunter, A.K. (2007). Comparison of strong anion-exchangers for the purification of a PEGylated protein. Journal of Chromatography A 1147, 172-182.

Parveen, S. y Sahoo, S.K. (2006). Nanomedicine. Clinical applications of polyethylene glycol conjugated proteins and drugs. Clinical Pharmacokinetics 45, 965-988.

Reddy, K.R., Modi, M.W. y Pedder, S. (2002). Use of peginterferon alfa-2a (40 kD) (Pegasys R ) for the treatment of hepatitis C. Advanced Drug Delivery Reviews 54, 571-586.

Rito-Palomares, M. (2004). Practical application of aqueous two-phase partition to process development for the recovery of biological products. Journal of Chromatography B 807, 3-11.

Roberts, M.J., Bentley, M.D. y Harris, J.M. (2002). Chemistry for peptide and protein PEGylation. Advanced Drug Delivery Reviews 54, 459-476.

Ryan, S.M., Mantovani, G., Wang, X., Haddleton, D.M. y Brayden, D.J. (2008). Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opinion on Drug Delivery 5,371-383.

Sato, H. (2002). Enzymatic procedure for sitespecific PEGylation of proteins. Advanced Drug Delivery Reviews 54, 487-504.

Seely, J.E., Buckel, S.D., Green, P.D. y Richey, C.W. (2005). Making site-specific PEGylation work. BioPharm International, 30-42.

Sookkumnerd, T. y Hsu, J.T. (2000). Purification of PEG-protein conjugates by countercurrent distribution in aqueous two-phase systems. Journal of Liquid Chromatography & Related Technologies 23, 497-503.

Vandertol-Vanier, H.A., Vazquez-Duhalt, R, Tinoco, R. y Pickard, M.A. (2002). Enhanced activity by poly(ethylene glicol) modification of Coriolopsis gallica laccase. Journal of Industrial Microbiology and Biotecnhology 29, 214-220.

Veronese, F.M. y Mero, A. (2008). The impact of PEGylation on biological therapies. BioDrugs 22, 315-329.

Veronese, F.M. y Pasut, G. (2005). PEGylation, successful approach to drug delivery. Drug Discovery Today 10, 1451-1458.

Wang, Y.S., Youngster, S., Grace, M., Bausch, J., Bordens, R. y Wyss, D.F. (2002). Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Advanced Drug Delivery Reviews 54, 547-570.

Wattendorf, U. y Merkle, H.P. (2008). PEGylation as a tool for the biomedical engineering of surface modified microparticles. Journal of Pharmaceutical Sciences 97, 4655-4669.

Zhai, Y., Zhao, Y., Lei, J., Su, Z. y Ma, G. (2009). Enhanced circulation half-life of site-specific PEGylated rhG-CSF: optimization of PEG molecular weight. Journal of Biotechnology 142, 259-266.
How to Cite
Mayolo-Deloisa, K. P., & Rito-Palomares, M. (2020). PEGYLATED PROTEINS: PRODUCTION, PURIFICATION, AND APPLICATIONS. Revista Mexicana De Ingeniería Química, 9(1), 17-27. Retrieved from